| Autor: |
Dzimianski JV; Department of Biomolecular Engineering, University of California Santa Cruz, Santa Cruz, CA, USA., Lorig-Roach N; Department of Biomolecular Engineering, University of California Santa Cruz, Santa Cruz, CA, USA., O'Rourke SM; Department of Biomolecular Engineering, University of California Santa Cruz, Santa Cruz, CA, USA., Alexander DL; Ontera Inc., Santa Cruz, CA, USA., Kimmey JM; Department of Microbiology and Environmental Toxicology, University of California Santa Cruz, Santa Cruz, CA, USA., DuBois RM; Department of Biomolecular Engineering, University of California Santa Cruz, Santa Cruz, CA, USA. rmdubois@ucsc.edu. |
| Abstrakt: |
Serological testing to evaluate antigen-specific antibodies in plasma is generally performed by rapid lateral flow test strips that lack quantitative results or by high complexity immunoassays that are time- and labor-intensive but provide semi-quantitative results. Here, we describe a novel application of biolayer interferometry for the rapid detection of antigen-specific antibody levels in plasma samples, and demonstrate its utility for quantification of SARS-CoV-2 antibodies. Our biolayer interferometry immunosorbent assay (BLI-ISA) utilizes single-use biosensors in an automated "dip-and-read" format, providing real-time optical measurements of antigen loading, plasma antibody binding, and antibody isotype detection. Complete semi-quantitative results are obtained in less than 20 min. BLI-ISA meets or exceeds the performance of high complexity methods such as Enzyme-Linked Immunosorbent Assay (ELISA) and Chemiluminescent Immunoassay. Importantly, our method can be immediately implemented on existing BLI platforms for urgent COVID-19 studies, such as serosurveillance and the evaluation of vaccine candidates. In a broader sense, BLI-ISA can be developed as a novel diagnostic platform to evaluate antibodies and other biomolecules in clinical specimens. |
